Project | Test group (n = 208) | Control group (n = 204) | P Value |
---|---|---|---|
Before treatment | |||
MMP-2 (ng/L) | 182.51 ± 12.66 | 180.36 ± 12.92 | 0.09 |
MMP-9 (ng/L) | 207.24 ± 22.50 | 203.31 ± 23.11 | 0.08 |
CD4+ % | 33.15 ± 4.24 | 33.12 ± 4.13 | 0.94 |
CD8+ % | 30.51 ± 3. 39 | 30.76 ± 3.54 | 0.46 |
CD4+/CD8+ | 1.17 ± 0. 25 | 1.18 ± 0.21 | 0.66 |
After treatment | |||
MMP-2 (ng/L) | 32.51 ± 4.11 | 76.37 ± 6.39 | < 0.0001 |
MMP-9 (ng/L) | 34.38 ± 4.82 | 77.13 ± 7.09 | < 0.0001 |
CD4+ % | 37.82 ± 5.12 | 33.73 ± 4.73 | < 0.0001 |
CD8+ % | 27.05 ± 3.83 | 29.18 ± 3.10 | < 0.0001 |
CD4+/CD8+ | 1.33 ± 0.21 | 1. 16 ± 0. 20 | < 0.0001 |